Honored and proud to co-lead the Phase III @NRGonc GY035 trial—advancing options for patients w/ advanced/recurrent, p53‑mutated, MMR‑proficient endometrial cancer. Grateful to our patients, collaborators, and study team for making this work possible.🧬💉📈
NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab vs Carboplatin, Paclitaxel, Bevacizumab vs Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in Treatment of pMMR, TP53 Mutated Advanced or Recurrent #EndometrialCancer. @amandanfader @TabonesMTView quoted post on X